Projects Funded This Year

From February 2001 to December 2021, The Morgan Adams Foundation has provided more than $7.6 million in research funds for pilot, seed, and translational studies.

 

 

 

“The crucial support from Morgan Adams continues to fund all those high-risk, high-reward studies that would otherwise not be possible,” said Rajeev Vibhakar, MD, PhD and Program Leader of Pediatric Neuro-Oncology at the University of Colorado School of Medicine and Children’s Hospital Colorado. “It is these studies that often lead to novel, groundbreaking research projects and subsequent therapeutic interventions.”

2022 Projects Funded

Omics “in the round”
Nicholas Foreman

Bioinformatic analysis
Nicholas Foreman, Rajeev Vibhakar

Preclinical in-vivo testing of experimental therapeutics in ependymoma
Nicholas Foreman

Development of humanized immune system PDX model for evaluating the tumor-immune interaction in pediatric brain tumors
Nicholas Foreman, Andrea Griesinger

NF1-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors: spatial transcriptomics to determine methods disease progression and transformation
Nicholas Foreman

Identification and validation of novel targets identified from the CRISPR druggable target screening in both H3K27M and WT histone-DIPG
Sujatha Venkataraman, Adam Green, Rajeev Vibhakar

Targeting Radiation Resistance in medulloblastoma
Bethany Veo, Rajeev Vibhakar

Synthesis and testing of humanized CD99 antibody with the novel 10D1 clone sequence in DIPG
Sujatha Venkataraman, Rajeev Vibhakar

Pre-clinical testing of novel gene-edited CAR-T cell therapy targeting pediatric tumors, DIPG, and Ewing Sarcoma
Sujatha Venkataraman

Analysis of stem cell and immune cell populations in pediatric high-grade glioma
Adam Green

Demonstrate the Impact of MMP-9 Knockdown in 3 Novel Adamantinomatous Craniopharyngioma (ACP) Models
Todd Hankinson

Multiplex Immunofluoresence spatial distribution in Adamantinomatous Craniopharyngioma (ACP)
Todd Hankinson

Mechanisms of BMI1 regulation in ATRT
Irina Alimova, Rajeev Vibhakar

Evaluation of autophagy inhibition clinical trial samples to assess biologic markers of response
Jean Mulcahy-Levy, Masanori Hayashi

 

Expanded application of zotiraciclib to pediatric brain tumors
Nathan Dahl

Development of Chimeric Antigen Receptor expressing macrophages to target pediatric brain tumors
Siddhartha Mitra, Sujatha Venkataraman, Mark Eric Kohler

Preclinical testing of the small molecule inhibitors Navitoclax, and Binimetinib using ex vivo Adamantinomatous Craniopharyngioma Tissue
Todd Hankinson

Combining radiation therapy with PRMT5 inhibition in diffuse midline glioma
Adam Green

CDK8 as a regulator of Myc driven Medulloblastoma
Dong Wang, Rajeev Vibhakar

Neurocognitive Function in the Pediatric Hematology, Oncology Population
Claire Fraley

Prospective Investigation of Childhood Cancer Early Death & Its Potential Causes
Adam Green

Development of a public web-based tool to refine interpretable AI tools in pediatric neuro-oncology
Todd Hankinson

Functional screening of pediatric high-grade glioma and radiation-induced glioma patient-derived models
Sujatha Venkataraman, Adam Green

Translating discoveries from brain tumor genomics into new therapeutic strategies
David A. Solomon

Identifying novel targets for MYC amplified Osteosarcoma 
Masanori Hayashi

Utilization of Single Cell Analysis Tools to Identify Targetable Phenotypes for Pediatric AML
Amanda Winters

Myeloid Cell Phenotype in the Setting of Chimeric Antigen Receptor T-cell Therapy
Hannah Lust

Inhibition of multi-functional BETs in relapsed and metastatic osteosarcoma
Pankita H. Pandya

Institutional Partners